ASSOCIATION BETWEEN IMMUNOSUPPRESSIVE THERAPY AND INCIDENT RISK OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS.

MLA

Hoa S., et al. Association between Immunosuppressive Therapy and Incident Risk of Interstitial Lung Disease in Systemic Sclerosis. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1305118006&authtype=sso&custid=ns315887.

APA

Hoa S., Bernatsky S., Baron M., Proudman S., Stevens W., Sahhar J., Wang M., Steele R.J., Nikpour M., & Hudson M. (2021). Association between Immunosuppressive Therapy and Incident Risk of Interstitial Lung Disease in Systemic Sclerosis.

Chicago

Hoa S., Bernatsky S., Baron M., Proudman S., Stevens W., Sahhar J., Wang M., Steele R.J., Nikpour M., and Hudson M. 2021. “Association between Immunosuppressive Therapy and Incident Risk of Interstitial Lung Disease in Systemic Sclerosis.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1305118006&authtype=sso&custid=ns315887.